One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects

Jonathan F. Lovell, Kazutoyo Miura, Yeong Ok Baik, Chankyu Lee, Jeong Yoon Lee, Young Shin Park, Ingi Hong, Jung Hyuk Lee, Taewoo Kim, Sang Hwan Seo, Jae Ouk Kim, Manki Song, Chung Jong Kim, Jae Ki Choi, Jieun Kim, Eun Ju Choo, Jung Hyun Choi

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Objective: EuCorVac-19 (ECV-19), an adjuvanted liposome-displayed receptor binding domain (RBD) COVID-19 vaccine, previously reported interim Phase 2 trial results showing induction of neutralizing antibodies 3 weeks after prime-boost immunization. The objective of this study was to determine the longer-term antibody response of the vaccine. Methods: To assess immunogenicity 6 and 12 months after vaccination, participants in the Phase 2 trial (NCT04783311) were excluded if they: 1) withdrew, 2) reported COVID-19 infection or additional vaccination, or 3) exhibited increasing Spike (S) antibodies (representing possible non-reported infection). Following exclusions, of the 197 initial subjects, anti-S IgG antibodies and neutralizing antibodies were further assessed in 124 subjects at the 6-month timepoint, and 36 subjects at the 12-month timepoint. Results: Median anti-S antibody half-life was 52 days (interquartile range [IQR]:42-70), in the “early” period from 3 weeks to 6 months, and 130 days (IQR:97-169) in the “late” period from 6 to 12 months. There was a negative correlation between initial antibody titer and half-life. Anti-S and neutralizing antibody responses were correlated. Neutralizing antibody responses showed longer half-lives; the early period had a median half-life of 120 days (IQR:81-207), and the late period had a median half-life of 214 days (IQR:140-550). Conclusion: These data establish antibody durability of ECV-19, using a framework to analyze COVID-19 vaccine-induced antibodies during periods of high infection.

Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalInternational Journal of Infectious Diseases
Volume138
DOIs
StatePublished - Jan 2024

Bibliographical note

Publisher Copyright:
© 2023 The Author(s)

Keywords

  • COVID-19
  • Durability
  • Humoral immunity
  • Liposome
  • RBD
  • SARS-CoV-2
  • Vaccine

Fingerprint

Dive into the research topics of 'One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects'. Together they form a unique fingerprint.

Cite this